How Biotech AI And Robotics Bridge Bottlenecks To Impact Global Health

As biotech and pharma adopt AI to accelerate R&D, manufacturing bottlenecks constrain health innovation. Biotech AI and robotics emerges to bridge these gaps and drive impacts across health.

The NVIDIA State of AI in Healthcare and Life Sciences: 2026 Trends report found that 70% of biotech, pharma, and healthtech industry organizations are actively using AI, up from 63% in 2025. A majority (65%) are using AI for data analytics and data science, while almost half of pharma say they are using AI agents for drug discovery and biomarker identification. Manufacturing was not mentioned or included in the survey, despite the critical role it plays.

Benchling’s report, which also notes a dramatic increase in AI adoption in R&D, also fails to provide any data on how manufacturing is planning to keep pace. According to the report, over the next 1-2 years, only 38% plan to adopt workflow orchestration and AI in manufacturing and supply chains.

In this report, Filippos Tourlomousis, Founder and CEO, Biological Lattice Industries (BLI), walks readers through biotech technologies poised to impact global health, the AI R&D bottlenecks, the role of automated robotics manufacturing, and the supply chain opportunities for companies that want to help.

Which Biotech Technologies Have the Greatest Potential to Impact Global Health?

Biological Lattice Industries (BLI), tech stack is developed to automate the entire DMTA loop — design, make, test, analyze — the cycle every product innovation depends on, using cyber-physical AI agents.

Working in three layers, Loominus designs and orchestrates, BioLoom prints, and MetaLab formulates. The company recognizes the advances made in different areas of biotech but says that what hasn’t kept pace is the computational and robotic infrastructure to conceive, design, validate, launch, and manufacture products. DMTA loops are still running in manual, trial and error mode, the company says.